跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
macrophage cell therapy
首页
药物
macrophage cell therapy
macrophage cell therapy
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
MODIFIED MONOCYTES/MACROPHAGE EXPRESSING CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF
EP 3328402 A4
申请人: UNIV PENNSYLVANIA
优先权: 2015
CN
EP
US
WO
27 件公开
Chlorite in the treatment of neurodegenerative disease
US 7105183 B2
申请人: UNIV CALIFORNIA
优先权: 2005
CN
US
8 件公开
MITOCHONDRIAL-DERIVED PEPTIDES AND ANALOGS THEREOF FOR USE AS A THERAPY FOR AGE-RELATED DISEASES INCLUDING CANCER
EP 4149511 B1
申请人: UNIV SOUTHERN CALIFORNIA
优先权: 2020
CN
EP
US
WO
5 件公开
MACROPHAGE TRANSFECTION METHOD
EP 2146748 A1
申请人: ORBIS HEALTH SOLUTIONS
优先权: 2007
CN
EP
US
WO
4 件公开
ERYTHROID LINEAGES DERIVED FROM PLURIPOTENT CELLS
EP 4599051 A2
申请人: GARUDA THERAPEUTICS INC
优先权: 2022
CN
EP
US
WO
4 件公开
ALLOGENEIC HUMAN MACROPHAGES FOR CELL THERAPY
EP 4338745 A1
申请人: UNIV DRESDEN TECH
优先权: 2022
CN
EP
WO
4 件公开
MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF) TARGETING FOR THE TREATMENT OF NON-SMALL CELL LUNG CANCER
EP 4615582 A1
申请人: UNIV TEXAS
优先权: 2022
EP
US
WO
3 件公开
IMMUNE CELLS WITH REDUCED ANDROGEN RECEPTOR (AR) LEVEL, AND METHODS OF THEIR USE TO ENHANCE ANTI-CANCER THERAPY
US 2024400991 A1
申请人: UNIV OREGON HEALTH & SCIENCE
优先权: 2021
US
WO
3 件公开
ENRICHMENT OF CD16+ MONOCYTES TO IMPROVE DENDRITIC CELL VACCINE QUALITY
EP 3268012 A4
申请人: HEALTH RESEARCH INC
优先权: 2015
EP
US
2 件公开
PATIENT SPECIFIC INDUCED PLURIPOTENT STEM CELL DERIVED MACROPHAGES FOR CELL BASED THERAPY
EP 4695381 A1
申请人: UNIV TEXAS
优先权: 2023
EP
WO
2 件公开
第 1 / 8 页
上一页
下一页
药物
反馈